Fig. 1From: 99mTc-labelled S-HYNIC certolizumab pegol in rheumatoid arthritis and spondyloarthritis patients: a biodistribution and dosimetry studyCell survival of TNF sensitive L929s cells following exposure to 0–300 U/mL of human TNF solutions and preincubated with 250, 50 and 10 ng/ml 99mTc-S-HYNIC CZP. In the control experiment, the cells are exposed to TNF but no inhibitor (99mTc-S-HYNIC CZP) is addedBack to article page